
    
      The PK and 24 week data has been published in Pediatric Infectious Diseases Journal. It
      showed that plasma drug concentrations of saquinavir, lopinavir and ritonavir were at the
      higher limits of expected ranges for adult treatment at approved dosages (1000/100 mg BID for
      saquinavir, 400/100 mg BID for lopinavir/r). The regimen was well tolerated and showed
      significant CD4 rise and VL decline at 48 weeks.
    
  